



## **Publication of insider information pursuant to Art. 17 MAR**

**Carl Zeiss Meditec is aiming for the upper end of its revenue forecast for the current year and expects strong earnings**

**Jena, July 15, 2019**

Carl Zeiss Meditec (ISIN: DE0005313704) has achieved revenue of around EUR 1,028 million in the first nine months of fiscal year 2018/19, based on preliminary data. This corresponds to revenue growth of around 11 % vs. the previous year's value of EUR 926.3 million. After adjustment for currency effects<sup>1</sup>, growth amounted to approximately 9 %.

Earnings before interest and taxes (EBIT) is expected to amount to around EUR 184 million after nine months (previous year: EUR 134.8 million). EBIT margin (EBIT / revenue in %) is approximately 17.9% (previous year: 14.6%). A positive development of the product mix with a higher share of consumables contributed to this increase. Earnings per share grew to around EUR 1.22 (previous year: EUR 0.92).

For fiscal year 2018/19, Carl Zeiss Meditec now expects revenue at the upper end of the previous forecast range of EUR 1,350 to EUR 1,420 million. Due to the strong current trend, EBIT margin is expected to exceed the previous forecast range of 15.0 % to 17.5 %.

From today's point of view and in light of planned strategic investments in research & development, management does not expect a further increase in EBIT margin in the coming fiscal year 2019/20. Carl Zeiss Meditec expects to provide a more precise forecast for fiscal year 2019/20 with publication of fiscal year 2018/19 results by Dec 6, 2019. The nine months quarterly statement for fiscal year 2018/19 will be published on August 9, 2019.

### **Contact for investors and press**

Sebastian Frericks  
Director Investor Relations  
Carl Zeiss Meditec AG  
Tel.: +49 3641 220-116  
E-Mail: [investors.meditec@zeiss.com](mailto:investors.meditec@zeiss.com)

---

<sup>1</sup> Currency-adjusted revenue growth is calculated by converting revenue of the previous year's period with current exchange rates.



#### **Carl Zeiss Meditec AG**

Carl Zeiss Meditec AG (ISIN: DE 0005313704), which is listed on MDAX and TecDax of the German stock exchange, is one of the world's leading medical technology companies. The Company supplies innovative technologies and application-oriented solutions designed to help doctors improve the quality of life of their patients. The Company offers complete solutions, including implants and consumables, to diagnose and treat eye diseases. The Company creates innovative visualization solutions in the field of microsurgery.

With approximately 3,050 employees worldwide, the Group generated revenue of €1,280.9m in fiscal year 2017/18 (to 30 September).

The Group's head office is located in Jena, Germany, and it has subsidiaries in Germany and abroad; more than 50 percent of its employees are based in the USA, Japan, Spain and France. The Center for Application and Research (CARIn) in Bangalore, India and the Carl Zeiss Innovations Center for Research and Development in Shanghai, China, strengthen the Company's presence in these rapidly developing economies. Around 41 percent of Carl Zeiss Meditec AG's shares are in free float. The remaining approx. 59 percent are held by Carl Zeiss AG, one of the world's leading groups in the optical and optoelectronic industries.

For further information visit: [www.zeiss.com/med](http://www.zeiss.com/med)